Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov;12(11):1737-9.
doi: 10.3201/eid1211.060143.

VEB-1 in Achromobacter xylosoxidans from cystic fibrosis patient, France

Catherine Neuwirth  1 , Carine Freby, Agathe Ogier-Desserrey, Stéphanie Perez-Martin, Anne Houzel, André Péchinot, Jean-Marie Duez, Fréderic Huet, Eliane Siebor
Affiliations

VEB-1 in Achromobacter xylosoxidans from cystic fibrosis patient, France

Catherine Neuwirth et al. Emerg Infect Dis. 2006 Nov.

Abstract

Multidrug-resistant Achromobacter xylosoxidans was recovered from the sputum of a patient with cystic fibrosis. The VEB-1 extended-spectrum β-lactamase was detected on a class 1 integron. This first report of a VEB-1–producing isolate in this population requires further investigation to determine its distribution.

PubMed Disclaimer

Figures

Figure
Figure
A) Oval indicates area of synergy between ticarcillin (TIC) and TIC plus clavulanic acid (CA). B) Arrows point to inhibition zone around third-generation disks with and without CA. AMX, amoxicillin; FEP, cefepime; CAZ, ceftazidime; CTX, cefotaxime; CF, cefalotin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev. 2004;17:57–71. 10.1128/CMR.17.1.57-71.2004 - DOI - PMC - PubMed
    1. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005;25:95–109. 10.1016/j.ijantimicag.2004.10.002 - DOI - PubMed
    1. Conway SP, Brownlee KG, Denton M, Peckam DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med. 2003;2:321–32. - PubMed
    1. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol. 2001;39:3942–5. 10.1128/JCM.39.11.3942-3945.2001 - DOI - PMC - PubMed
    1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–86. 10.1128/CMR.18.4.657-686.2005 - DOI - PMC - PubMed

Substances

Associated data